As the healthcare industry continues to face data challenges, PurpleLab® is making significant investments in its data and infrastructure to reinforce its position as a trusted leader in real-world data (RWD). We’ve recently secured several new data sources that will dramatically improve the comprehensiveness and composition of our data.(RWD) and real-world evidence (RWE) earlier in the product lifecycle to inform decision-making.

Although randomized controlled trials remain a cornerstone of evidence generation, pharmaceutical and biotech companies are increasingly recognizing the necessity of leveraging real-world data
(RWD) and real-world evidence (RWE) earlier in the product lifecycle to inform decision-making.

Biomarker testing guides selection of targeted therapies in non–small cell lung cancer (NSCLC). Despite its clinical importance, the extent of provider variation in biomarker testing practices and its correlation with patient outcomes has not been thoroughly explored.

Clinical trials are designed to evaluate the safety and efficacy of new therapies or medical devices. During these trials, evidence is gathered to determine if the asset is safe for patients, providing the intended benefit at the appropriate dosage, as well as identifying and minimizing any potential side effects.

In pharmaceutical development, where most therapies never reach the market, early and strategic data investments can make all the difference.

This study was run to understand variations in treatment with resulting shifts in care management that aligns with patient preferences and migraine-specific care and observe if a relationship exists between racially diverse patients seeking care and healthcare provider (HCP) specialties, including alternative medicine providers. Diane Faraone, PharmD, Karina D’Angelo PhD., Andreas Lysandropoulos, MD, PhD. Background…

Clinical trials are just the start. Discover how real-world data help life sciences companies implement market access strategies designed to get new drugs to patients who need them.

In today’s outcomes-driven healthcare landscape, real-world data (RWD) and real-world evidence (RWE) have emerged as critical tools to demonstrate clinical value, return on investment (ROI) and long-term impact beyond controlled trial environments.

Generic drugs don’t usually grab headlines. They’re dependable, low-cost and mostly stay in the background. But behind that generic label is a global system that’s far more fragile, and far more important, than it seems. Today, that system is under serious pressure. The United States is facing everything from supply chain disruptions and political instability…